Nektar Therapeutics (NKTR) Misses Q1 EPS by 8c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $60.97 --0%
Revenue Growth %: -11.4%
Financial Fact:
Total revenue: 36.34M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -11.4%
Financial Fact:
Total revenue: 36.34M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.24), $0.08 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $16.31 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order
- Coherus Oncology hires Oppenheimer to sell biosimilar assets
- General Mills (GIS) Tops Q1 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
